Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience.
Carr MJ, Sun J, DePalo D, Rothermel LD, Song Y, Straker RJ, Baecher K, Louie RJ, Stahlie EHA, Wright GP, Naqvi SMH, Kim Y, Sarnaik AA, Karakousis GC, Lowe MC, Delman KA, van Akkooi ACJ, Ollila DW, Collichio F, Zager JS. Carr MJ, et al. Among authors: collichio f. Ann Surg Oncol. 2022 Feb;29(2):791-801. doi: 10.1245/s10434-021-10910-5. Epub 2021 Oct 14. Ann Surg Oncol. 2022. PMID: 34648098
High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
Klauber-Demore N, Kuzmiak C, Rager EL, Ogunrinde OB, Ollila DW, Calvo BF, Kim HJ, Meyer A, Dees C, Graham M 2nd, Collichio FA, Sartor CI, Metzger R, Carey LA. Klauber-Demore N, et al. Among authors: collichio fa. Am J Surg. 2004 Oct;188(4):386-9. doi: 10.1016/j.amjsurg.2004.06.022. Am J Surg. 2004. PMID: 15474431
Axillary lymph node count is lower after neoadjuvant chemotherapy.
Neuman H, Carey LA, Ollila DW, Livasy C, Calvo BF, Meyer AA, Kim HJ, Meyers MO, Dees EC, Collichio FA, Sartor CI, Moore DT, Sawyer LR, Frank J, Klauber-DeMore N. Neuman H, et al. Among authors: collichio fa. Am J Surg. 2006 Jun;191(6):827-9. doi: 10.1016/j.amjsurg.2005.08.041. Am J Surg. 2006. PMID: 16720159 Clinical Trial.
Historical review of melanoma treatment and outcomes.
Lee C, Collichio F, Ollila D, Moschos S. Lee C, et al. Among authors: collichio f. Clin Dermatol. 2013 Mar-Apr;31(2):141-7. doi: 10.1016/j.clindermatol.2012.08.015. Clin Dermatol. 2013. PMID: 23438377 Review.
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Andtbacka RH, et al. Among authors: collichio f. J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26. J Clin Oncol. 2015. PMID: 26014293 Clinical Trial.
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, Amatruda T, Zager JS, Cranmer L, Hsueh E, Chen L, Shilkrut M, Kaufman HL. Andtbacka RH, et al. Among authors: collichio f. Ann Surg Oncol. 2016 Dec;23(13):4169-4177. doi: 10.1245/s10434-016-5286-0. Epub 2016 Jun 24. Ann Surg Oncol. 2016. PMID: 27342831 Free PMC article. Clinical Trial.
79 results